OraVerse: Distribution to wholesalers who do not hold an establishment license for sale of the product in Canada
Last updated
Summary
Product
OraVerse
Issue
Health products - Establishment/Site licensing
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| OraVerse | OraVerse | DIN 02421666 | Solution | PHENTOLAMINE MESYLATE 0.4 MG / 1.7 ML | D05004B, D05004D |
Issue
Distribution of a prescription drug to wholesaler(s) who did not hold an establishment license.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Recalling Firm:
Novocol Pharmaceutical of Canada Inc. (subsidiary of Septodont)
25 Wolseley Court
Cambridge, ON
Canada
N1R 6X3
Market Authorization Holder:
Septodont 58 Rue Du Pont De Creteil
St-Maur-Des-Fosses
Val-De-Marne
France
94107
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type III
Recall date
Identification number
RA-81212
Get notified
Receive emails about new and updated recall and safety alerts.